- Home
- EDSA vs AEI Comparison
EDSA vs AEI Comparison
Compare EDSA & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- AEI
- Stock Information
- Founded
- EDSA 2015
- AEI 2014
- Country
- EDSA Canada
- AEI United States
- Employees
- EDSA N/A
- AEI N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- AEI Building operators
- Sector
- EDSA Health Care
- AEI Real Estate
- Exchange
- EDSA Nasdaq
- AEI Nasdaq
- Market Cap
- EDSA 6.1M
- AEI 12.0M
- IPO Year
- EDSA N/A
- AEI N/A
- Fundamental
- Price
- EDSA $1.73
- AEI $1.00
- Analyst Decision
- EDSA Strong Buy
- AEI
- Analyst Count
- EDSA 1
- AEI 0
- Target Price
- EDSA $21.00
- AEI N/A
- AVG Volume (30 Days)
- EDSA 30.6K
- AEI 62.1K
- Earning Date
- EDSA 02-07-2025
- AEI 11-14-2024
- Dividend Yield
- EDSA N/A
- AEI N/A
- EPS Growth
- EDSA N/A
- AEI N/A
- EPS
- EDSA N/A
- AEI N/A
- Revenue
- EDSA N/A
- AEI $13,191,488.00
- Revenue This Year
- EDSA N/A
- AEI N/A
- Revenue Next Year
- EDSA N/A
- AEI N/A
- P/E Ratio
- EDSA N/A
- AEI N/A
- Revenue Growth
- EDSA N/A
- AEI N/A
- 52 Week Low
- EDSA $1.55
- AEI $0.46
- 52 Week High
- EDSA $5.99
- AEI $2.05
- Technical
- Relative Strength Index (RSI)
- EDSA 31.51
- AEI 40.25
- Support Level
- EDSA $1.73
- AEI $0.86
- Resistance Level
- EDSA $1.99
- AEI $1.20
- Average True Range (ATR)
- EDSA 0.19
- AEI 0.13
- MACD
- EDSA 0.02
- AEI -0.01
- Stochastic Oscillator
- EDSA 18.00
- AEI 31.66
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.